Fact 20 of 20 in the story · Saturday 14 November, 09h00

Wegovy et Mounjaro remboursés : les centres spécialisés de l'obésité saturés

Depuis juin 2026, Wegovy et Mounjaro sont remboursés sous conditions en France. Les centres spécialisés de l'obésité croulent sous les demandes de patients.

In brief

Health event (severity: low) nationwide, first detected on 14 November 2026 at 09:00. Reported by 1 source (1 article), last updated on 14 November 2026 at 09:00. Part of the story “Anti-obesity GLP-1 in France: reimbursement, diverted uses and health alerts”.

Category: Health
Severity: Low
Place: National
Detected: 14 Nov, 09h00
Updated: 14 Nov, 09h00
Reference: no.19512

What changed in the story at that point

Just before07h19 · −1 h 41

Wegovy : une Gersoise témoigne de sa perte de poids

Info· Health · no.19461

Here · 09h00

Latest fact of the story to date

Who is covering it, and from what angle

Method

1Centre

1 article · 1 source · 1 bord sur 3 · outlets: left 0, centre 1, right 0

Story angles

This event does not yet have its own comparison: here is the story's Anti-obesity GLP-1 in France: reimbursement, diverted uses and health alerts.

All three sides cover the arrival of Wegovy in tablet form, but the left emphasizes industrial competition and reimbursement conditions, the center develops waiting times, the parallel market and patient testimonies, while the right highlights the non-reimbursable nature and practical information (price, side effects).

Left

Highlights the rivalry between Novo Nordisk and Eli Lilly on a fast-growing global market, as well as the lack of reimbursement for pills and side effects to be aware of.

Centre

Develops concrete consequences: waiting times of up to 18 months, parallel market, position of drug treatments compared with bariatric surgery and patient testimonies.

Right

Emphasizes the non-reimbursable nature of oral Wegovy and offers a practical format listing price, side effects and reimbursement.

Common points

=Wegovy in tablet form is available in pharmacies in France from Monday, November 2
=The oral version is not reimbursed
=Wegovy had until now been administered by injection in France

Divergences

≠The left emphasizes competition between laboratories (Novo Nordisk, Eli Lilly), an angle little present on the right
≠The center insists on waiting times of up to 18 months and the parallel market, absent from the left and right titles provided
≠The center and right detail price and side effects in a practical format, the left favoring the industrial and regulatory angle

Written by an AI from headlines and extracts only of all events in the story · 2 Nov, 03h41

Lire les sources · 1 article, 1 source

Publication order

09h00
BFMTV / RMCCentreAnalysisvia BFMTV – Info en continu14 Nov
Wegovy, Mounjaro…Que valent ces nouveaux traitements contre l’obésité?
On parle souvent du poids avec des chiffres et des injonctions, mais derrière, il y a des vies, des corps que l’on commente, des regards que l’on subit, parfois pendant des années. Depuis juin 2026, Wegovy et Mounjaro, ces deux molécules, sont remboursées sous conditions en France. Résultat: les centres spécialisés de l’obésité croulent sous les demandes, avec des délais qui dépassent désormais un an dans certains établissements. Que changent vraiment ces traitements ? Que découvre-t-on du regard des autres quand le corps change ? Dans ce nouvel épisode du podcast santé, Margaux de Frouville e

Wegovy et Mounjaro remboursés : les centres spécialisés de l'obésité saturés

What changed in the story at that point

Who is covering it, and from what angle

Lire les sources · 1 article, 1 source

Further reading